Search
DE EN
more info

Contact:
Phone:+49 0761 1514 440 Fax:+49 0761 1514 460 Email: info[at]falkfoundation.org

Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 3/2025

Edition 2/2025

Edition 1/2025

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Esophagus to Small Intestine

Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease

Clin Gastroenterol Hepatol. 2025;23(1):144-153.e22

Meyer A, Miranda S, Drouin J, Weill A, Carbonnel F, Dray-Spira R

Colon to Rectum

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): Phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Lancet. 2025;405(10472):33-49

Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KHG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group

Colon to Rectum

Deep learning model using stool pictures for predicting endoscopic mucosal inflammation in patients with ulcerative colitis

Am J Gastroenterol. 2025;120(1):213-224

Lee JW, Woo D, Kim KO, Kim ES, Kim SK, Lee HS, Kang B, Lee YJ, Kim J, Jang BI, Kim EY, Jo HH, Chung YJ, Ryu H, Park SK, Park DI, Yu H, Jeong S; IBD Research Group of KASID and Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD)

Colon to Rectum

Withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission: A randomised placebo-controlled clinical trial of GETECCU

Gut. 2025;74(3):387-396

Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M; EXIT Study group of GETECCU

Colon to Rectum

Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: A parallel, open-label randomised controlled trial, the ACTIVE trial

Gut. 2025;74(2):197-205

Amiot A, Seksik P, Meyer A, Stefanescu C, Wils P, Altwegg R, Vuitton L, Plastaras L, Nicolau A, Pereira B, Duveau N, Laharie D, Mboup B, Boualit M, Allez M, Rajca S, Chanteloup E, Bouguen G, Bazin T, Goutorbe F, Richard N, Moussata D, Vicaut E, Peyrin-Biroulet L

Colon to Rectum

Mucosal healing with vedolizumab in patients with chronic pouchitis: EARNEST, a randomized, double-blind, placebo-controlled trial

Clin Gastroenterol Hepatol. 2025;23(2):321-330.e3

Jairath V, Feagan BG, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, Bressler B, Ferrante M, Hart A, Lindner D, Escher A, Jones S, Shen B, Travis S

Colon to Rectum

Clinical pharmacist counselling improves long-term medication safety and patient-reported outcomes in anti-TNF-treated patients with inflammatory bowel diseases: The prospective, randomized AdPhaNCED trial

Inflamm Bowel Dis. 2025;31(1):77-86

Plechschmidt J, Fietkau K, Hepp T, Dietrich P, Fischer S, Krebs S, Neurath MF, Dörje F, Atreya R

Colon to Rectum

Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study

Lancet Gastroenterol Hepatol. 2025;10(3):234-247

Atia O, Shavit-Brunschwig Z, Lev-Tzion R, Stein R, Broide E, Urlep D, Hyams J, Weiss B, Aloi M, Assa A, Gerasimidis K, Nichols B, Russell RK, Turner D

Colon to Rectum

Impact of prenatal and postnatal maternal IBD status on offspring’s risk of IBD: A population-based cohort study

Gut. 2025;74(2):206-213

Bonfils L, Poulsen G, Agrawal M, Julsgaard M, Torres J, Jess T, Højgaard Allin K